TALPHERA, INC. annual report, FY2013

Business context and reporting period

The supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, not a filing under the name TALPHERA, INC. AcelRx was a clinical-stage specialty pharmaceutical company developing treatments for acute and breakthrough pain. Its lead candidate, Zalviso, was under FDA review; none of its candidates had been approved, and it had no product-sale revenue.

Financial performance and position

FY 2013 revenue included $27.4 million recognized from the Grünenthal collaboration and $2.1 million from the U.S. Army research grant. The collaboration’s $30 million upfront payment was allocated among deliverables: $27.4 million was recognized for the license, while $2.6 million remained deferred. There was no revenue from product sales; product margins are therefore not applicable.

Operating cash flow was a use of $0.5 million, compared with $24.6 million used in 2012. The 2013 figure was substantially affected by noncash items, including warrant and contingent-put-liability remeasurement, stock compensation and a debt-extinguishment loss; it should not be read as a normalized cash-burn rate. Investing cash flow used $6.9 million and financing cash flow provided $47.9 million.

Year-end debt was $15.0 million principal outstanding ($14.4 million carrying value, net). The amended Hercules facility provides up to $40 million: $15 million was drawn, a further $10 million was optionally available through June 30, 2014, and a final $15 million tranche depended on FDA approval of Zalviso. The debt is secured by substantially all assets other than intellectual property, subject to the agreement’s terms. No product-sales profitability or operating margins were reported.

Fourth-quarter 2013 snapshot

Unaudited Q4 revenue was $27.6 million, operating expenses were $7.6 million and net income was $17.8 million ($0.41 basic and $0.39 diluted per share). Q4 2012 revenue was $1.7 million and net loss was $10.5 million. The Q4 2013 profit was not evidence of product-sales profitability: the quarter included the large collaboration-related revenue recognition, while full-year results also included substantial other expense, primarily associated with fair-value changes in warrant liabilities and debt amendment accounting.

Material changes versus the prior comparable period

• Revenue rose to $29.5 million from $2.4 million, mainly due to the Grünenthal agreement; operating expenses increased 13% to $36.2 million.
• Net loss narrowed to $23.4 million from $33.4 million, while the loss from operations narrowed to $6.7 million from $29.7 million. The annual net result was materially affected by non-operating, substantially noncash warrant remeasurement expense and a debt-extinguishment loss.
• Cash and investments increased by $43.9 million, supported by the July 2013 equity offering, the Grünenthal upfront payment and borrowing. Common shares outstanding increased from 37.1 million to 43.1 million during the year.
• Research and development expense rose 6% to $26.3 million; general and administrative expense increased 37% to $9.9 million.

Outlook, commentary and principal risks

• The FDA accepted the Zalviso NDA for filing and set a July 27, 2014 PDUFA action date. Assuming approval, management expected first U.S. commercial sales in Q1 2015; both dates and the launch were contingent, not assured.
• Management expected existing resources, together with potential Hercules borrowing, to support operations through at least 2015, based on assumptions including FDA approval in Q3 2014 and a Q1 2015 launch. Delays, additional regulatory requirements, or higher-than-expected costs could shorten that runway.
• Grünenthal received exclusive commercialization rights for Zalviso in the EU, specified European countries and Australia. AcelRx received $30 million upfront and was eligible for about $220 million in additional development, regulatory, manufacturing and sales-related payments, plus tiered royalties and fees. These contingent amounts were not assured; AcelRx remained responsible for device regulatory work and product supply.
• ARX-04 met its Phase 2 primary endpoint at the 30 mcg dose; FDA discussions informed a planned Phase 3 program, with initiation targeted for the second half of 2014. Further ARX-02 and ARX-03 development depended on partnership resources.
• Key risks include FDA approval, labeling and opioid-related safety or REMS requirements; the need for additional capital; commercial uptake, pricing, reimbursement and hospital formulary access; reliance on contract manufacturers and limited qualified supply sources; controlled-substance quotas; and competition and intellectual-property risks.
• The company reported no material pending litigation. Management and the auditor concluded internal control over financial reporting was effective as of year-end; the financial-statement audit opinion was unqualified.

Important facts for investors to verify

• Confirm the registrant identity and filing: the supplied document names AcelRx Pharmaceuticals, Inc., although the request metadata names TALPHERA, INC.
• Check subsequent FDA decisions and actual timing, scope and conditions of any Zalviso approval or launch; the filing’s dates were forward-looking expectations.
• Reconcile the collaboration’s upfront cash, recognized revenue, deferred revenue and contingent milestones, and assess what payments were actually achieved.
• Assess cash burn excluding noncash warrant remeasurement and other unusual items, and confirm the availability and conditions of each Hercules tranche and the company’s financing runway.
• Verify commercial-scale manufacturing readiness, backup supply arrangements and required regulatory qualification of the manufacturing facilities.
• Review the warrant-liability accounting and its effect on reported net income or loss, as well as dilution from equity offerings, warrants, options and potential further financing.